The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | SIERRA: STRIDE as a first-line therapy in poor-prognosis patients with advanced uHCC
Lorenza Rimassa, MD, Hunimed University, Milan, Italy, shares insight into the Phase IIIb SIERRA study (NCT05883644), which is evaluating single tremelimumab regular interval durvalumab (STRIDE) as a first-line therapy in patients with advanced unresectable hepatocellular carcinoma (uHCC). This study included patients that had been excluded from the registration study for STRIDE, including those with less well-preserved liver function, poorer clinical conditions and with portal vein thrombosis. The safety profile was found to be consistent with previous data, but slightly worse efficacy was observed, which may be caused by the decreased prognosis of the patients rather than the efficacy of the combination. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
